Lannett approved for oxycodone hydrochloride caps

PHILADELPHIA — Lannett Co. on Monday announced that its abbreviated new drug application for oxycodone hydrochloride capsules, 5 mg, has been approved by the Food and Drug Administration. It is the equivalent to oxycodone hydrochloride capsules, 5 mg, of Lehigh Valley Technologies.



“Oxycodone Hydrochloride Capsules, 5 mg, represents our third product approved by the FDA thus far in 2014 and, importantly, adds to our goal of vertical integration,” said Arthur Bedrosian, president and CEO of Lannett. “We hope to receive additional product approvals in the near future while we continue to develop our robust pipeline.”



Total sales for the year ended June 2014 for oxycodone hydrochloride capsules, 5 mg, were $7.1 million, according to IMS data. The company said it expects to ship the product in the coming months.